As PD-1hi CD8+ T cells are linked with immune exhaustion and are the prime target of immune-checkpoint blockade treatment for HCC38, these data support the potential benefit of immunotherapy in intermediate HCC. The gene discussed is CD8A; the disease is hepatocellular carcinoma.